FEDERATED HERMES, INC. - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 202 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2020. The put-call ratio across all filers is 1.14 and the average weighting 0.1%.

Quarter-by-quarter ownership
FEDERATED HERMES, INC. ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$1,302,917
-31.4%
70,276
-59.1%
0.00%
-40.0%
Q2 2023$1,899,555
+37.7%
171,750
+67.2%
0.01%
+66.7%
Q1 2023$1,379,879
+9798.0%
102,746
+9016.8%
0.00%
Q4 2022$13,941
+1294.1%
1,127
+1510.0%
0.00%
Q3 2022$1,000
-99.9%
70
-99.9%
0.00%
-100.0%
Q4 2021$915,000
+91400.0%
56,198
+5619700.0%
0.00%
Q1 2020$1,000
-100.0%
1
-100.0%
0.00%
-100.0%
Q4 2019$12,018,000
+15307.7%
96,984
+9826.7%
0.03%
Q2 2019$78,000
-99.5%
977
-99.3%
0.00%
-100.0%
Q1 2019$15,724,000
+599.5%
140,565
+530.3%
0.04%
+550.0%
Q4 2018$2,248,000
-79.1%
22,301
-73.8%
0.01%
-76.0%
Q3 2018$10,744,000
+1791.5%
85,025
+1156.8%
0.02%
+1150.0%
Q2 2018$568,000
+60.9%
6,765
+17.9%
0.00%
+100.0%
Q1 2018$353,000
+720.9%
5,740
+684.2%
0.00%
Q4 2017$43,0000.0%732
-2.3%
0.00%
Q3 2017$43,000
-41.9%
749
+22.6%
0.00%
Q2 2017$74,000
-81.7%
611
-82.9%
0.00%
-100.0%
Q1 2017$404,000
+39.8%
3,570
+34.4%
0.00%0.0%
Q4 2016$289,000
-43.8%
2,656
-14.9%
0.00%0.0%
Q3 2016$514,000
-92.5%
3,122
-96.9%
0.00%
-95.8%
Q4 2013$6,842,000
-1.1%
100,2000.0%0.02%
-11.1%
Q3 2013$6,916,000
+54.2%
100,200
+0.2%
0.03%
+50.0%
Q2 2013$4,484,000100,0000.02%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q2 2020
NameSharesValueWeighting ↓
Samsara BioCapital, LLC 640,688$9,514,0001.49%
CM Management, LLC 45,000$668,0000.50%
EULAV Asset Management 660,000$9,801,0000.26%
DLD Asset Management, LP 225,200$3,346,0000.24%
Virtus ETF Advisers LLC 21,387$318,0000.14%
GSA CAPITAL PARTNERS LLP 79,145$1,175,0000.12%
Hennion & Walsh Asset Management, Inc. 136,720$2,030,0000.11%
ALTRINSIC GLOBAL ADVISORS LLC 168,800$2,507,0000.08%
Inspire Investing, LLC 31,868$473,0000.06%
DUALITY ADVISERS, LP 51,196$760,0000.06%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders